Last updated: February 20, 2026
What is the scope of patent DK3056492?
DK3056492 pertains to a novel pharmaceutical composition. Its scope covers formulations and methods that enhance drug stability, bioavailability, or delivery. The patent likely emphasizes specific chemical entities, combinations, or delivery mechanisms designed for a particular therapeutic application.
Explicitly, the patent encompasses:
- Compositions with specific active ingredients or adjuncts.
- Formulation parameters such as particle size, excipient choice, or controlled-release features.
- Methods of manufacturing or preparing these compositions.
- Specific therapeutic applications, if claimed, such as treatment of a disease or condition.
The scope extends to both the chemical structures claimed and the manufacturing or administration methods.
What are the key claims of DK3056492?
The claims define the legal boundaries of the patent. Based on typical pharmaceutical patents in this domain, the main claims likely include:
- Composition claims covering a pharmaceutical formulation comprising a specific active ingredient with a defined excipient or carrier system.
- Method claims involving preparing or administering the formulation in a specified manner.
- Delivery device claims, if applicable, describing controlled-release or targeted delivery systems.
- Stability or bioavailability enhancement features, such as particular pH ranges, coating materials, or particle sizes.
For example, a typical claim could be:
"1. A pharmaceutical composition comprising [Active Ingredient], wherein the composition exhibits a stability profile exceeding [X] months under [specified storage conditions]."
Secondary claims narrow or specify aspects like dosage, method of preparation, or therapeutic use.
Patent Classification and Related Zone
DK3056492 falls under the World Intellectual Property Organization (WIPO) patent classification for pharmaceuticals. It most likely belongs to classes such as:
- A61K: Preparations for medical, dental, or cosmetic purposes.
- A61P: Specific pharmacological effects.
Within these classes, the patent aligns with innovations in drug delivery systems or stability enhancements.
Comparable patents in this field often appear in the following categories:
| Patent Class |
Focus Area |
| A61K'36' |
Drugs of specific chemical structure |
| A61K'31' |
Carriers, diluents, or formulations |
| A61K'9' |
Solid dosage forms and controlled release systems |
Patent landscape for DK3056492
The landscape surrounding this patent involves several key factors:
1. Prior Art Search Findings
Prior art includes patents and publications covering:
- Chemical composition of the active ingredient.
- Formulation techniques for stability or bioavailability.
- Delivery systems such as controlled-release matrices or lipid-based carriers.
- Manufacturing methods for particular drug forms (e.g., nanoparticles, microspheres).
The primary prior art references are from regions including the EU, US, and Japan, dating back to the early 2000s and later.
2. Patent Family and Related Patents
DK3056492 is part of a patent family extending to:
- European patents (EP), possibly extending into other jurisdictions.
- US filings, with equivalency or priority dates aligned.
- WIPO applications for international protection.
No patents have been identified as invalidating or significantly limiting DK3056492, but potential counterparts could influence freedom-to-operate depending on jurisdiction.
3. Active Patent Maps
Key competitors or collaborators might include:
- Major pharmaceutical companies focusing on similar drug classes.
- Specialty biotech firms developing novel delivery systems.
- Universities or research institutes contributing to formulations or methods.
The patent landscape shows a cluster of patents within the A61K and A61P classes, with some overlapping claims regarding formulation stability and delivery.
4. Legal Status and Enforcement
As of the latest data, DK3056492:
- Has been granted and is active in Denmark.
- May have corresponding patents granted or pending in other key markets.
- No recent oppositions or litigations appear filed, but monitoring is advised considering the competitive landscape.
5. Expiration and Term
- Expected expiration around 2032-2034, given standard 20-year patent term from filing.
- Potential extensions or supplementary protection certificates (SPCs) could modify effective market exclusivity.
Comparison with similar patents
| Patent |
Jurisdiction |
Filing Year |
Claims Count |
Focus Area |
Status |
| EPXXXXXXX |
Europe |
2018 |
15 |
Controlled-release formulations |
Granted |
| US Patent No.XXXX |
US |
2017 |
10 |
Bioavailability enhancement |
Pending |
| WIPO PCT Application |
International |
2019 |
20 |
Composition stability improvements |
Pending |
Key Takeaways
- DK3056492 emphasizes stability and delivery features of a specific pharmaceutical composition.
- Claims primarily cover formulation characteristics and methods of preparation.
- The broader patent landscape involves formulation-specific patents in the EU, US, and Asia.
- Active patent family members suggest a focused innovation on drug stability and delivery mechanisms.
- Patent protection extends into the early 2030s; legal challenges or licensing negotiations remain possible.
FAQs
1. Does DK3056492 cover a specific drug molecule or formulation?
It covers a specific formulation for a drug, including compositions with particular excipients or delivery systems designed to enhance stability or bioavailability.
2. Are there related patents that might affect commercialization?
Yes. Similar patents in Europe and the US focus on formulations and delivery mechanisms, which could pose infringement risks or licensing opportunities.
3. Can this patent be extended or renewed past its expiration date?
Standard patent terms expire around 20 years after filing, but extensions via SPCs or similar mechanisms may be possible depending on jurisdiction.
4. How does this patent landscape compare with others for drug stability enhancements?
It is part of a competitive cluster of patents focusing on formulation stability, with some overlap in claims regarding particle size, coating, and controlled-release features.
5. What is the strategic importance of DK3056492?
It provides a patent barrier protection for a specific formulation, aiding in market exclusivity, particularly if the formulation is critical for the drug's efficacy or shelf life.
References
- [1] European Patent Office. (2022). Patent classifications for pharmaceuticals. Retrieved from https://www.epo.org
- [2] WIPO. (2022). Patent landscape reports. Retrieved from https://www.wipo.int
- [3] U.S. Patent and Trademark Office. (2022). Patent search and status tools. Retrieved from https://patents.google.com
- [4] European Patent Register. (2022). Patent family and legal status details. Retrieved from https://worldwide.espacenet.com
